Cisplatin and oral vinorelbine chemotherapy along with radiation for treatment of locally advanced lung cancer

A phase II trial evaluating progression free survival with cisplatin and oral vinorelbine plus radiation for Stage III Non Small Cell Lung Cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000003279

Acronym

CoVERT

Enrollment

Registered

2009-01-06

Start date

2008-08-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The study is looking at efficacy of combination of oral vinorelbine and cisplatin with radiation for locally advanced lung cancer. The combination is unique as it combine oral with intravenous treatment.

Interventions

Oral vinorelbine 50 mg/m2 day 1,8 along with intravenous cisplatin at dose of 50 mg/m2 day 1,8 every 3 weeks for 2 cycles along with 60 Gy radiation treatment at the rate of 2 Gy per fraction. All the treatment is given simultaneously.

Study design

Allocation

Non-randomised trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Histologically or cytologically (fine needle aspiration) proven non-small cell lung cancer Performance status 0-1 Forced expiratory volume (FEV1) >1 Ltr Adequate hematology and biochemistry

Exclusion criteria

Neuropathy > Grade 1 Uncontrolled medical disorder Malabsorption syndrome Women if pregnant or breast-feeding

Outcome results